{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:24Z","timestamp":1792786104262,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice"},{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/rheumatology\/key104","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T15:12:09Z","timestamp":1522854729000},"page":"1390-1399","source":"Crossref","is-referenced-by-count":51,"title":["Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients"],"prefix":"10.1093","volume":"57","author":[{"given":"Walter P","family":"Maksymowych","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P","family":"Sherlock","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dona","family":"Fleishaker","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Hendrikx","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S","family":"Kanik","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"key\n\t\t\t\t2019020208592701500_key104-B1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B4","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2004.032441","article-title":"Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept","volume":"64","author":"Rudwaleit","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B7","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2214\/AJR.05.1423","article-title":"MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis","volume":"187","author":"Bredella","year":"2006","journal-title":"Am J Roentgenol"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10067-007-0726-7","article-title":"Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings","volume":"27","author":"Goh","year":"2008","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B10","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/ar4464","article-title":"Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers","volume":"16","author":"Wei\u00df","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B11","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3899\/jrheum.120131","article-title":"Defining the minimally important change for the Spondyloarthritis Research Consortium of Canada spine and sacroiliac joint magnetic resonance imaging indices for ankylosing spondylitis","volume":"39","author":"Maksymowych","year":"2012","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B13","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B16","first-page":"1186","article-title":"Metric properties of the SPARCC score of the sacroiliac joints - data from baseline, 3-month, and 12-month followup in the SPACE cohort. J","volume":"42","author":"van den Berg","year":"2015","journal-title":"Rheumatol"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B17","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/annrheumdis-2012-201999","article-title":"MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor","volume":"71","author":"Machado","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B18","first-page":"415","article-title":"Positive correlation between inflammation on sacroiliac joint MRI and serum C-terminal telopeptide of type-I collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis","volume":"35","author":"Kang","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B20","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/ar4548","article-title":"Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis","volume":"16","author":"Pedersen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/annrheumdis-2017-211605","article-title":"Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis","volume":"77","author":"Maksymowych","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019020208592701500_key104-B22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/8\/1390\/27696423\/key104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T23:55:22Z","timestamp":1571010922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/8\/1390\/4987910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,4,26]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key104","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,4,26]]}}}